In early May, Alfredo Zurlo took over the role of Chief Medical Officer at Berlin-based clinical-stage immuno-oncology company Glycotope. He joins from Mologen, where he held the position of CMO, too, and was also a member of the Executive Board.

Dutch gene therapy play uniQure has nominated Jack Kaye to its Board of Directors. Kaye will also chair the uniQure’s Audit Committee.

RS Genomics, formed to provide broad access to CRISPR/Cas9 IP, has appointed Eric Rhodes as its new CEO. He joins the company from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer.

Exceptional inventors from all over Europe have been honoured with the European Inventor Award 2016. With the award, the European Patent Office recognises the achievements of inventors from Denmark, France, Germany, the Netherlands, the UK and the US.

Finding a treatment for depression that is well-tolerated and effective is difficult and time-consuming. UK scientists have now developed a blood test to predict whether common antidepressants will work in a patient.

In early June, the Hungarian National Association of Drugmakers (Magyosz) elected István Hodász as its general chairman. Hodász is CEO and managing director of the Egis Pharmaceuticals Plc, a unit of France’s Servier.

Funded with €9m by the French government, biomaterial player Global Bioenergies is getting closer to its goal to build the first bio-isobutene plant. IBN-One, sugar beet producer Cristal Union and cosmetics giant L’Oreal are also on board.

GATC Biotech, a leading provider of advanced genome analysis and diagnostic services, launched today INVIEW ONCOPANEL, a comprehensive multigene cancer panel for solid tumour profiling.

When Sanofi sells its animal health division Merial, CEO Carsten Hellmann will join Danish allergy specialist ALK Albello as the next President and CEO. He will also give up his seat on the Executive Committee and his position of Executive Vice President at Sanofi.

A few months ago, the EMA introduced its new accelerated access scheme, PRIME. Now, the agency has published the first few therapies that will use the chance to speed their breakthrough meds through the approval process.